title: Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
abstract: In almost 30 years since the introduction of HMG-CoA reductase inhibitors (statins), no other class of lipid modulators has entered the market. Elevation of high-density lipoprotein-cholesterol (HDL-C) via inhibiting cholesteryl ester transfer protein (CETP) is an attractive strategy for reducing the risk of cardiovascular events in high-risk patients. Transfer of triglyceride and cholesteryl ester (CE) between lipoproteins is mediated by CETP; thus inhibition of this pathway can increase the concentration of HDL-C. Torcetrapib was the first CETP inhibitor evaluated in phase III clinical trials. Because of off-target effects, torcetrapib raised blood pressure and increased the concentration of serum aldosterone, leading to higher cardiovascular events and mortality. Torcetrapib showed positive effects on cardiovascular risk especially in patients with a greater increase in HDL-C and apolipoprotein A-1 (apoA-1) levels. The phase III clinical trial of dalcetrapib, the second CETP inhibitor that has entered clinical development, was terminated because of ineffectiveness. Dalcetrapib is a CETP modulator that elevated HDL-C levels but did not reduce the concentration of low-density lipoprotein cholesterol (LDL-C). Both heterotypic and homotypic CE transfer between lipoproteins are mediated by some CETP inhibitors, including torcetrapib, anacetrapib, and evacetrapib, while dalcetrapib only affects the heterotypic CE transfer. Dalcetrapib has a chemical structure that is distinct from other CETP inhibitors, with a smaller molecular weight and a lack of trifluoride moieties. Moreover, dalcetrapib is a pro-drug that must be hydrolyzed to a pharmacologically active thiol form. Two other CETP inhibitors, anacetrapib and evacetrapib, are currently undergoing evaluation in phase III clinical trials. Both molecules have shown beneficial effects by increasing HDL-C and decreasing LDL-C concentration. The success of anacetrapib and evacetrapib remains to be confirmed upon the completion of phase III clinical trials in 2017 and 2015, respectively. Generally, the concentration of HDL-C has been considered a biomarker for the activity of CETP inhibitors. However, it is not clear whether a fundamental relationship exists between HDL-C levels and the risk of coronary artery diseases. The most crucial role for HDL is cholesterol efflux capacity in which HDL can reverse transport cholesterol from foam cells in atherosclerotic plaques. In view of the heterogeneity in HDL particle size, charge, and composition, the mere concentration of HDL-C may not be a good surrogate marker for HDL functionality. Recent clinical studies have reported that increased HDL functionality inversely correlates with the development of atherosclerotic plaque. Future development of CETP inhibitors may therefore benefit from the use of biomarkers of HDL functionality.
authors: Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA.
authors: Amir Hooshang
authors: AH
authors: Mohammadpour
authors: Fatemeh
authors: F
authors: Akhlaghi
mesh_terms: D000577:Amides; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000494:pharmacology / Q000627:therapeutic use; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D008076:Cholesterol, HDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D004952:Esters; D006801:Humans; D023303:Oxazolidinones / Q000494:pharmacology / Q000627:therapeutic use; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use; D013438:Sulfhydryl Compounds / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000577:Amides; D000924:Anticholesteremic Agents; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D004952:Esters; D023303:Oxazolidinones; D011804:Quinolines; D013438:Sulfhydryl Compounds; D001569:Benzodiazepines; C411602:dalcetrapib; C483909:torcetrapib; C568301:evacetrapib; C530884:anacetrapib
references: Int J Clin Pharmacol Ther. 2012 Aug;50(8):584-94
references: 22578199
references: JAMA. 2008 Jun 4;299(21):2524-32
references: 18523221
references: J Lipid Res. 2010 Dec;51(12):3443-54
references: 20861162
references: Arteriosclerosis. 1988 Nov-Dec;8(6):737-41
references: 3196218
references: Circulation. 1998 Nov 10;98(19):2088-93
references: 9808609
references: J Clin Pharmacol. 2009 Jan;49(1):80-7
references: 19004846
references: Eur Heart J. 1995 Jan;16(1):5-13
references: 7737222
references: Circulation. 1989 Jan;79(1):8-15
references: 2642759
references: JAMA. 1995 Aug 16;274(7):539-44
references: 7629981
references: Int J Clin Pharmacol Ther. 2012 Apr;50(4):248-56
references: 22456295
references: J Vis Exp. 2012 Mar 06;(61):e3810
references: 22414908
references: Nature. 2000 Jul 13;406(6792):203-7
references: 10910363
references: Biochem Pharmacol. 2013 Feb 1;85(3):439-47
references: 23228697
references: J Lipid Res. 2012 Sep;53(9):1755-66
references: 22550134
references: Clin Drug Investig. 2011;31(5):325-35
references: 21366361
references: Int J Clin Pharmacol Ther. 2013 Mar;51(3):215-8
references: 23357838
references: J Clin Invest. 1980 Nov;66(5):892-900
references: 7430351
references: Xenobiotica. 2011 May;41(5):430-6
references: 21348578
references: N Engl J Med. 2007 Mar 29;356(13):1304-16
references: 17387129
references: Expert Opin Investig Drugs. 2010 Oct;19(10):1135-45
references: 20738227
references: Atherosclerosis. 2003 Sep;170(1):31-8
references: 12957680
references: N Engl J Med. 2007 Nov 22;357(21):2180-3
references: 17984168
references: Br J Clin Pharmacol. 2010 Dec;70(6):825-33
references: 21175438
references: J Lipid Res. 2003 Jun;44(6):1080-93
references: 12639975
references: Clin Pharmacol Ther. 2009 Oct;86(4):430-7
references: 19587642
references: N Engl J Med. 2012 Nov 29;367(22):2089-99
references: 23126252
references: N Engl J Med. 2011 Jan 13;364(2):127-35
references: 21226578
references: Am J Med. 1977 May;62(5):707-14
references: 193398
references: Lancet. 2007 Dec 8;370(9603):1907-14
references: 18068514
references: Circulation. 2009 Aug 18;120(7):628-35
references: 19687369
references: Lancet. 2007 Jul 14;370(9582):153-160
references: 17630038
references: Eur Heart J. 2012 Apr;33(7):857-65
references: 22345126
references: N Engl J Med. 2007 Nov 22;357(21):2109-22
references: 17984165
references: Circulation. 1997 Jan 7;95(1):69-75
references: 8994419
references: J Lipid Res. 1990 Sep;31(9):1569-75
references: 2246610
references: Am J Cardiol. 2009 Nov 16;104(10 Suppl):32E-8E
references: 19895942
references: Br J Clin Pharmacol. 2012 Feb;73(2):219-31
references: 21762205
references: JAMA. 2007 Aug 15;298(7):786-98
references: 17699012
references: Circ Cardiovasc Genet. 2009 Feb;2(1):26-33
references: 20031564
references: Clin Chim Acta. 2011 Jun 11;412(13-14):1213-20
references: 21420943
references: Vasc Health Risk Manag. 2012;8:323-31
references: 22661899
references: Nature. 1989 Nov 23;342(6248):448-51
references: 2586614
references: N Engl J Med. 1999 Aug 5;341(6):410-8
references: 10438259
references: J Clin Pharmacol. 2010 Oct;50(10):1188-201
references: 20489031
references: J Lipid Res. 2006 Mar;47(3):537-52
references: 16326978
references: J Lipid Res. 2012 Mar;53(3):540-547
references: 22180633
references: Circ Res. 2004 Oct 15;95(8):764-72
references: 15486323
references: N Engl J Med. 2007 Apr 19;356(16):1620-30
references: 17387131
references: Biopharm Drug Dispos. 2011 Dec;32(9):525-9
references: 22031172
references: Drug Metab Dispos. 2008 Nov;36(11):2185-98
references: 18694908
references: J Cardiovasc Pharmacol. 2006 Feb;47(2):196-204
references: 16495756
references: J Intern Med. 2008 Mar;263(3):256-73
references: 18271871
references: Bioorg Med Chem Lett. 2012 May 1;22(9):3056-62
references: 22497761
references: Br J Clin Pharmacol. 2009 May;67(5):520-6
references: 19552746
references: Lipids Health Dis. 2009 Apr 06;8:14
references: 19348677
references: Drug Metab Dispos. 2008 Oct;36(10):2064-79
references: 18653742
references: JAMA. 2008 Mar 19;299(11):1265-76
references: 18349088
references: Clin Pharmacol Ther. 2008 Dec;84(6):679-83
references: 18580870
references: N Engl J Med. 1990 Nov 1;323(18):1234-8
references: 2215607
references: Lancet. 2011 Oct 29;378(9802):1547-59
references: 21908036
references: Drug Metab Dispos. 2010 Mar;38(3):474-83
references: 20016053
references: JAMA. 2008 Jun 18;299(23):2777-88
references: 18560005
references: Drug Metab Dispos. 2010 Mar;38(3):459-73
references: 20016052
references: Clin Ther. 2011 Jun;33(6):754-65
references: 21704240
references: JAMA. 1986 Nov 28;256(20):2835-8
references: 3773200
references: Atherosclerosis. 2010 Jun;210(2):353-61
references: 20079494
references: Am J Cardiol. 2004 Feb 1;93(3):307-12
references: 14759379
references: Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):257-60
references: 17229967
references: Lancet. 2012 Aug 11;380(9841):572-80
references: 22607825
references: J Lipid Res. 2009 Apr;50 Suppl:S201-6
references: 19023137
references: Pharmacotherapy. 1987;7(6):198-210
references: 3328165
references: J Lipid Res. 2011 Dec;52(12):2169-2176
references: 21957197
references: Am Heart J. 2009 Dec;158(6):896-901.e3
references: 19958854
references: N Engl J Med. 2010 Dec 16;363(25):2406-15
references: 21082868
references: J Cardiovasc Pharmacol. 2012 Oct;60(4):390-6
references: 22820896
references: Curr Opin Lipidol. 2012 Aug;23(4):372-6
references: 22517614
references: Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1430-8
references: 20448206
references: Br J Clin Pharmacol. 2012 Jul;74(1):116-24
references: 22243494
references: Curr Opin Lipidol. 2004 Aug;15(4):393-8
references: 15243211
references: Br J Clin Pharmacol. 2009 Oct;68(4):535-45
references: 19843057
references: JAMA. 2011 Nov 16;306(19):2099-109
references: 22089718